| 參考文獻 |
Summary Literatures
Chapter 1
1. M. S. Lipsky, MD, and L. K. Sbarp, “From idea to market: the drug approval
process,” JABFP 14(5): 362-367 (2001).
2. S. Kraljevic, P. J. Stambrook, and K. Pavelic, “Accelerating drug discovery,”
EMBO reports 5(9): 837-842 (2004).
3. G. W. Caldwell, “Compound optimization in early- and late-phase drug discovery:
acceptable pharmacokinetic properties utilizing combined physicochemical, in
vitro and in vivo screens,” Current Opinion in Drug Discovery & Development 3
(1): 30-41 (2000).
4. J. Wechsler, “Manufacturers face new challenges battling global threats,” Pharm.
Tech. 30(8): 24-32 (2005).
5. L. Yu, S. M. Reutzel and G.. A. Stephenson, “Physical characterization of
polymorphic drugs: an integrated characterization strategy,” PSTT. 1(3): 118-127
(1998).
6. Y. Yoshihashi, E. Yonemochi, amd K. Terada, “Estimation of initial dissolution
rate of drug substance by thermal analysis: application for carbamazepine
hydrate,” Pharm. Devel. Tech. 7(1): 89-95 (2002).
7. D. J. W. Grant, “Theory and origin of polymorphism.”in,” Polymorphism in
pharmaceutical solids.” Edited by H.G. Brittain, Marcel Dekker, New York, pp
1-33 (1999).
8. L. X. Yu, M. S. Furness, A. Raw, K. P. W. Outlaw, N. E. Nashed, E. Ramos, S. P.
F. Miller, R. C. Adams, F. Fang, R. M. Patel, F. O. Holcombe, Jr., Y. Y. Chiu, and
A. S. Hussain, “Scientific considerations of pharmaceutical solid polymorphism
in abbreviated new drug applications,” Pharm. Res. 20(4):531-536 (2003).
147
9. T. L. Threlfall, “Analysis of organic polymorphs a review,” Analyst. 120(10):
2435-2459 (1995).
10. S. L. Morissette, O. Almarsson, M. L. Peterson, J. F. Remenar, M.J. Read, A. V.
Lemmo, S. Ellis, M. J. Cima, C. R. Gardner. “High-throughput crystallization:
polymorphs, salts, co-crystals and solvates of pharmaceutical solids,” Adv. Drug.
Deliv. Rev. 56(3): 275-300 (2004).
11. S. Teychene, J. M. Auertret, and B. Biscans, “Determination of solubility profiles
of eflucimibe polymorphs: experimental and modeling,” J. Pharm. Sci.
95(4):871-882 (2006).
12. R. G. Cantera, M. G. Leza, and C. M. Bachiller, “Solid phases of tenoxicam,” J.
Pharm. Sci. 91(10): 2240-2251 (2002).
13. T. S. Kim, D. H. Kim, H. J. Im, K. Shimada, R. Kawajiri, T. Okubo, and H.
Murata, T. Mitani, “Improved lifetime of an OLED using aluminum (III) tris
(8-hydroxyquinolate),” Science and Technology of Advanced Materials. 5(3):
331–337(2004).
14. A. Chimmalgi, D. J. Hwang, C. P. Grigoropoulos, “Nanoscale rapid melting and
crystallization of semiconductor thin films,” NANO LETTERS. 5(10):1924-1930
(2005).
15. K.J. Kim, H.S. Kim., “Coating of energetic materials using crystallization,”
Chem. Eng. Technol. 28(8): 946 – 951 (2005).
16. T. Threfall, “Crystallization of polymorphs: thermodynamic insight into the role
of solvent,” Org. Process Res. Dev. 4(5): 384-390 (2000).
17. S. Gracin and A. C. Rasmuson, “Solubility of phenylacetic acid,
p-hydroxyphenylacetic acid, p-aminophenylacetic acid, p-hydroxybenzoic acid,
and Ibuprofen in pure solvents,” J. Chem. Eng. Data. 47(6): 1379-1383 (2002).
148
18. M. Fujiwara, Z. K. Nagy, J. W. Chew, and Richard D. Braatz, “First-principles
and direct design approaches for the control of pharmaceutical crystallization,” J.
Process. Control. 15(5): 493-504 (2005).
19. S. Zhang, “Emerging biological materials through molecular self-assembly,”
Biotech. Adv. 20(5): 321-339 (2002).
20. A. Somogyi, F. Bochner and D. Foster, “Inside the isomers: the table of chiral
switches,” Australian. Prescriber. 27(2):47-49 (2004).
21. Z. Jane and D. J. W. Grant, “Relationship between physical properties and crystal
structures of chiral drugs,” J. Pharm. Sci. 86(10):1073-1078 (1997).
22. M. C. Gohel, “Overview on chirality and applications of stereo-selective
dissolution testing in the formulation and development work,” Dissolution.
Technologies. 10(3): 16-20 (2003).
23. G. G. Z. Zhang, S. Y. L. Paspal, R. Suryanarayanan, and D. J. W. Grant,
“Racemic compound of species of sodium ibuprofen: characterization and
polymorphic relationships,” J. Pharm. Sci. 92(7): 1356-1366 (2003).
24. S. Datta, and D. J. W. Grant, “Crystal structures of drugs: advances in
determination, prediction and engineering,” Nature 3(1):42-57 (2004).
25. T. R. Kommuru, M. A. Khan, and I. K. Reddy, “Racemate and enantiomers of
ketoprofen: phase diagram, thermodynamic studies, skin permeability, and use of
chiral permeation enhancers,” J. Pharm. Sci. 87(7): 833-840 (1998).
26. B. J. Armitage, J. F. Lampard, and A. Smith, “Composition of S(-) sodium
ibuprofen,” United States Patent, NO.5696165.
27. H. Potthast, J.B. Dressman, H.E. Junginger, K.K. Midha, H. Oeser, V.P. Shah, H.
Vogelpoel, and D.M. Barends, “Biowaiver monographs for immediate release
solid oral dosage forms: ibuprofen,” J. Pharm. Sci. 94(10): 2121-2131 (2005).
149
28. S. L. Morissette, Ö. Almarsson, M. L. Peterson, J. F. Remenar, M. J. Read, A. V.
Lemmo, S. Ellis, M. J. Cima, C. R. Gardner, “High-throughput crystallization:
polymorphs, salts, co-crystals and solvates of pharmaceutical solids,” Adv. Drug.
Deli. Rev. 56(3): 275-300 (2004).
29. G. L. Perlovich, S. V. Kurkov, L. K. Hansen, and A. Baure-Brandl,
“Thermodynamics of sublimation, crystal lattice energies, and crystal structures
of racemates and enantiomers: (+)- and (+/-)-ibuprofen,” J. Pharm. Sci.
93(3):654-666 (2004).
30. Y. Zhang, and D. J. W. Grant, “Similarity in structures of racemic and
enantiomeric ibuprofen sodium dihydrates,” Acta Crystallogr., Sect. C. C61(Pt 9):
m435-m438 (2005).
31. S. Byrn, K. Morris, and S. Comella, “Reducing time to market with a
science-based product management strategy,” Pharm. Tech. pp. 46-56 (2005).
32. L. X. Yu, R. A. Lionberger, A. S. Raw, R. D’Costa, H. Wu, and A. S. Hussain,
“Applications of process analytical technology to crystallization processes,” Adv.
Drug. Del. Rev. 56(3):349-369 (2004).
Chapter 2
1. A. K. Tiwary, “Modification of crystal habit and its role in dosage form
performance,” Drug. Dev. Ind. Pharm. 27(7): 699-709 (2001).
2. L. Yu, S. M. Reutzel and G.. A. Stephenson, “Physical characterization of
polymorphic drugs: an integrated characterization strategy,” PSTT 1(3): 118-127
(1998).
3. Y. Yoshihashi, E. Yonemochi, amd K. Terada, “Estimation of initial dissolution
rate of drug substance by thermal analysis: application for carbamazepine
150
hydrate,” Pharm. Devel. Tech. 7(1): 89-95 (2002).
4. D. J. W. Grant, “Theory and origin of polymorphism,” in H.G. Brittain,”
Polymorphism in pharmaceutical solids,” Marcel Dekker, New York, pp 1-33
(1999).
5. T. L. Threlfall, “Analysis of organic polymorphs. A review,” Analyst
120(10):2435-2460 (1995).
6. V. Koradia, G. Chawla, and A. K. Bansal, “Qualitative and quantitative analysis
of clopidogrel bisulphate polymorphs,” Acta Pharm. 54(3): 193–204(2004).
7. T. Hosokawa, S. Datta, A. R. Sheth and D. J. W. Grant, “Relationships between
crystal structures and thermodynamic properties of phenylbutazone solvates,”
Cryst. Eng. Comm. 6(44): 243-249 (2004).
8. G. Chawla and A. K. Bansal, “Challenges in polymorphism of pharmaceuticals,”
CRIPS 5(1): 9-12 (2004).
9. S. Mirza, I. Miroshnyk, J. Heinämäki, L. Christiansen, M Karjalainen, and J.
Yliruusi, “Infiuence of solvents on the variety of crystalline forms of
erythromycin,” AAPS Pharm. Sci. 5(3): 1-9 (2003).
10. A. R. Sheth and D. J. W. Grant, “Relationship between the structure and
properties of pharmaceutical crystals,” KONA (23): 36-48 (2005).
11. A. S. Raw, M. S. Furness, D. S. Gill, R. C. Adams, F. O. H. Jr, and L. X. Yu,
“Regulatory considerations of pharmaceutical solid polymorphism in abbreviated
new drug applications (ANDAs),” Adv. Drug Deliv. Rev. 56(3): 397-414 (2004)
12. R. Storey, R. Docherty, P. Higginson, C. Dallman, C. Gilmore, G. Barr and W.
Dong, “Automation of solid form screening procedures in the pharmaceutical
industry – How to avoid the bottlenecks,” Crystallography Reviews. 10(1): 45-56
(2004).
151
13. H. G. Brittain, “ Spectral methods for the characterization of polymorphs and
solvates,” J. Pharm. Sci. 86(4): 405-412 (1997).
14. K. Kimura, F. Hirayama, and K. Uekama, “Characterization of tolbutamide
polymorphs (Burger’s forms II and IV) and polymorphic transition behavior,” J.
Pharm. Sci. 88(4): 385-391 (1999).
15. S. Ito, M. Nishimura, Y. Kobayashi, S. Itai, K. Yamamoto, “Characterization of
polymorphs and hydrates of GK-128, a serotonin3 receptor antagonist,” Int. J.
Pharm. 151(2): 133-143 (1997).
16. T. J. Difeo, “Drug product development: a technical review of chemistry,
manufacturing, and controls information for the support of pharmaceutical
compound licensing activities,” Drug Dev. Ind. Pharm.29(9): 939-958 (2003).
17. B. Shah, V. K. Kakumanu, and A.K. Bansal, “Analystical techniques for
quantification of amorphous/crystalline phase in pharmaceutical solids,” J.
Pharm. Sci. 95(8): 1641-1665 (2006).
18. D. Giron, “Application of thermal analysis and coupled techniques in
pharmaceutical industry,” J. Therm. Anal. Calorim. 68(2): 335-357 (2001).
19. D. Giron, “Thermal analysis and calorimetric methods in the characterisation of
polymorphs and solvates,” Thermochim. Acta. 248(2):1-59 (1999).
20. X. Pan, T. Julian, and L. Augsburger, “Quantitative measurement of
indomethacin crystallinity in indomethacin-silica gel binary system using
differential scanning calorimetry and x-ray powder diffractometry,” Pharm. Sci.
Tech. 7 (1): E1-E7 (2006).
21. M. D. Ticehurst, R. A. Storey, and C. Watt, “Application of slurry bridging
experiments at controlled water activities to predict the solid-state conversion
152
between anhydrous and hydrated forms using theophylline as a model drug,” Int.
J. Pharm. 247(2): 1-10 (2001).
22. H. G. M. Edwards, E. Lawson, M. Matas, L. Shields, and P. York,
“Metamorphosis of caffeine hydrate and anhydrous caffeine,” J. Chem. Soc.
Perkin transactions, 2(10): 1985-1990 (1997).
23. H. Zhu, J. Xu, P. Varlashkin, S. Long, and C. Kidd, “Dehydration, Hydration
behavior, and structural analysis of Fenoprofen Calcium,” J. Pharm. Sci. 90(7):
845-859 (2001).
24. S. Agatonovic-Kustrin, V. Wu, T. Rades, D. Saville, and I.G. Tucker, “Powder
diffractometric assay of two polymorphic forms of ranitidine hydrochloride,” Int.
J. Pharm. 184(1): 107-114 (1999).
25. M. Otsuka, F. Kato, and Y. Matsuda, “Comparative evaluation of the degree of
indomethacin crystallinity by chemoinfometrical Fourie-Transformed
Near-Infrared Spectroscopy and conventional Powder X-ray Diffractiometry,”
Pharm. Sci. 2(1): 1-8 (2000).
26. Y. Hiramatsu, H. Suzuki, A. Kuchiki, H. Nakagawa, and S. Fujii, “X-ray
structure studies of lomeridine dihydrochloride polymorphs,” J. Pharm. Sci.
85(7): 761-766 (1996).
27. http://micro.magnet.fsu.edu/optics/lightandcolor/lenses.htm, “Introduction to
lenses.”
28. S. Amelinckx, D. V. Dyck, J. V. Landuyt, and G. V. Tendeloo, “Handbook of
microscopy,” Weinheim. New York. pp: 293-320 (1997).
29. O. Flint, “Chemical Aspects of food microscopy,” Anal. Pro. 29(3):106 (1992).
30. N. Rasenack, and B. W. Müller, “Crystal habit and tableting behavior,” Int. J.
Pharm. 244(1-2): 45-57 (2002).
153
31. J. Haleblian, and W. McCrone, “Pharmaceutical applications of polymorphism,”
J. Pharm. Sci. 58(8):911-929 (1969).
32. S. Mirza, I. Miroshnyk, J. Heinämäki, L. Christiansen, M. Karjalainen, and J.
Yliruusi, “Influence of solvents on the variety of crystalline forms of
Erythromycin,” AAPS. Pharm. Sci. 5(2): 1-8 (2003).
33. A. V. Bonsdorff-Nikander, J. Rantance, L. Christiansen, and J. Yliruusi,
“Optimizing the crystal size and habit of β-sitosterol in suspension,” AAPS
Pharm. Sci. Tech. 4(3): 1-8 (2003).
34. H. Cano, N. Gabas, J. P. Canselier, “Experimental study on the ibuprofen crystal
growth morphology in solution,” J. Crys. Grow. 224(7): 335-341 (2001).
35. P. A. Corrigan, V. E. Lyons, G. D. Baranes, and F. G. Hall, “Conductivity
measurements monitor waste streams,” Envir. Sci. Tech. 4(2): 116-121 (1970).
36. S. L. Wang, Y. J. Fu, W. C. Zhang, X. Sun, and Z. S. Gao, “In-line bulk
concentration measurement by method of conductivity in industrial KDP crystal
growth form aqueous solution,” Cryst. Res. Technol. 35(9): 1027-1034 (2000).
37. O. D. Linnikov, “spontaneous crystallization of potassium chloride from aqueous
and aqueous-ethanol solutions & Part I: Kinetics and mechanism of the
crystallization process,” Cryst. Res. Technol. 39(6): 516-528 (2004).
38. I. Kabdasli, S. A. Parsons, and O. Tünay, “Effect of major ions on induction time
of struvite precipitation,” CCACAA. 79(2): 243-251 (2006).
39. O. D. Linnikov, “Spontaneous crystallization of sodium chloride from aqueous
and aqueous-ethanol solutions & Part I: kinetics and mechanism of the
crystallization process,” Cryst. Res. Technol. 41(1): 10-17 (2006).
40. M. L. Balboni, “Process analytical technology,” Pharm. Tech. 27(10):54-61 (2003).
154
Chapter 3
1. K. J. Roberts, R. Docherty, P. Bennema, and L . A. M J Jetten, “The importance
of considering growth-induced conformational change in predicting the crystal
habit of benzophenone,” J. Phys. D:Appl. Phys. 26(B8): B7-B21 (1993).
2. R. Hiremath, S. W. Varney, and J. A. Swift, “Selective growth of less stable
polymorph of 2-iodo-4-nitroaniline on a self-assembled monolayer template,”
Chem. Commun. 7(23): 2676-267 (2004).
3. J. Aizenberg, “Crystallization in Patterns : A bio-inspired approach,” Adv. Mater.
16(15): 1295-1302 (2004).
4. S. P. Duddu, F. K.Y. Fung, and D. J. W. Grant, “Effect of doping with the
opposite enantiomer on the thermodynamic properties of (-)-ephedrinium
2-naphthalen -esulphonate crystals,” J. Phys. D:Appl. Phys. 26(B8): B41-B47
(1993).
5. T. S. Kim, D. H. Kim, H. J. Im, K. Shimada, R. Kawajiri, T. Okubo, H. Murata,
and T. Mitani, “Improved lifetime of an OLED using aluminum (III) tris
(8-hydroxyquinolate),” Sci. Tech. Adv. Matt. 5(3): 331–337 (2004).
6. A. Chimmalgi, D. J. Hwang, and C. P. Grigoropoulos, “Nanoscale rapid melting
and crystallization of semiconductor thin films,” Nanoletters 5(10): 1924-1930
(2005).
7. K.J. Kim, H.S. Kim, “Coating of energetic materials using crystallization,” Chem.
Eng. Technol. 28(8): 946 – 951 (2005).
8. T. Threfall, “Crystallization of polymorphs: thermodynamic insight into the role
of solvent,” Org. Process Res. Dev. 4(5): 384-390 (2000).
9. S. Gracin, and A. C. Rasmuson, “Solubility of phenylacetic acid,
p-hydroxyphenylacetic acid, p-aminophenylacetic acid, p-hydroxybenzoic acid,
155
and ibuprofen in pure solvents,” J. Chem. Eng. Data. 47(6): 1379-1383 (2002).
10. C. K. Chen, and A. K. Singh, “A “Bottom-Up” Approach to process development:
application of physicochemical properties of reaction products toward the
development of direct-drop processes,” Org. Process Res. Dev. 5(5): 508-513
(2001).
11. J. L. Hilden, C. E. Ryeyes, M. J. Kelm, j. S. Tan, J. G. Stowell, and K. R. Morris,
“Capillary precipitation of a highly polymorphic organic compound,” Cryst.
Growth. Des. 3(6): 921-926 (2003).
12. W. W. Wang, and Y. J. Zhu, “Synthesis of PbCrO4 and Pb2CrO5 rods via a
microwace-assisted ionic liquid methods,” Cryst. Growth. Des., 5(2): 505-507
(2005).
13. D. Braga, and F. Grepioni, “Making crystals from crystals: a green route to
crystal engineering and polymorphism,” Chem. Commun. 7(29): 3635–3645
(2005).
14. J. E. Aber, S. Arnold, and B. A. Garetz, “Strong dc electric field applied to
supersaturated aqueous glycine solution induces nucleation of the γ polymorph,”
Phys. Rev. Lett. 94(14): 145503 (2005).
15. M. Lang, A. L. Grzesiak, and A. J. Matzgar, “The Use of polymer heteronuclei
for crystalline polymorph selection,” J. Am. Chem. Soc. 124(50): 14834-14835
(2002).
16. A. M. Garcia, and E. S. Ghaly, “Preliminary spherical agglomerates of water
soluble drug using natural polymer and cross-linking technique,” J. Control.
Relea. 40(3): 179-186 (1996).
17. K. Sato, “Polymorphic transformations in crystal growth” J. Phys. D: Appl. Phys.
26(8B): B77-B84 (1993).
156
18. S. Kim, B. Lotz, M. Lindrud, K. Girard, T. Moore, K. Nagarajan, M. Alvarez, T.
Lee, F. Nikfar, M. Davidovich, S. Srivastava, and S. Kiang, “Control of the
particle properties of a drug substance by crystallization engineering and the
effect on drug product formulation,” Org. Pro. Res. Dev. 9(6):911-922 (2005).
19. L. Yu, and K. Ng, “Glycine crystallization during spray drying: The PH effect on
salt and polymorphic forms,” J. Pharm. Sci. 91(11): 2367-2375 (2002).
20. C. Wibowo, W. Chang, and K.M. Ng, “Design of integrated crystallization
systems,” AIChE. J. 47(11): 2474-2492 (2001).
21. W. I. Cross, N. Blagden, and R. J. Davey, “A whole output strategy for
polymorph screening: combining crystal structure prediction, graph set analysis,
and targeted crystallization experiments in the case of diflunisal,” Cryst. Growth.
Des. 3(2):151 -158 (2003).
22. L. C. Garzόn, and F. Martínez, “Temperature dependence of solubility for
ibuprofen in some organic and aqueous solvents,” J. Sol. Chem. 33(11):
1379-1395 (2004).
23. T. L. Therlfall, “Analysis of organic polymorphs a review,” Analyst 120:
2435-2460 (1995).
24. L. Yu, S. M. reutzel, and G. A. Stephenson, “Physical characterizationof
polymorphic drugs: an integrated characterization strategy,” PSTT. 1(3):118-217
(1998).
25. S. Datta, and D. J. W. Grant, “Crystal structures of drugs: advances in
determination, prediction and engineering,” Nat. Rev. Drug. Discov. 3(1): 42-57
(2004).
26. R. Hilfiker, J. Berghausen, F. Blatter, A. Burkhard, S. M. D. Paul, B. Freiermuth,
A. Geoffroy, U. Hofmeier, C. Marcolli, B. Siebenhaar, M. Szelagiewicz, A. Vit,
157
and M. V. Raumer, “Polymorphism-integrated approach from high-throughput
screening to crystallization optimization,” J. Therm. Anal. Calorim. 73(2):
429-440 (2003).
27. S. L. Morissette, O. Almarsson, M. L. Peterson, J. F. Remenar, M.J. Read, A. V.
Lemmo, S. Ellis, M. J. Cima, and C. R. Gardner. “High-throughput
crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical
solids,” Adv. Drug. Deliv. Rev. 56(3): 275-300 (2004).
28. D. Gao, and J. H. Raytting, “Use of solution calorimetry to determine the extent
of crystallinity of drugs and excipients,” Int. J. Pharm. 151(2): 183-192 (1997).
29. C. R. Navarro, and E. Dehne, “Salt weathering: influence of evaporation rate
supersaturation and crystallization pattern,” Earth Surf. Process. Landforms.
24(3): 191-209 (1999).
30. A. K. Tiwary, “Modification of crystal habit and its role in dosage from
performance,” Drug Dev. Ind. Pharm. 27(7): 699-709 (2001).
31. M. Lahav, and L. Leiserowitz, “The effect of solvent on crystal growth and
crystal habit,” Chem. Eng. Sci. 56(7): 2245-2253 (2001).
32. H. Cao, N. Gabas, and J. P. Canselier, “Experimental study on the ibuprofen
crystal growth crystal habit in solvent,” J. Cryst. Growth. 224(3-4): 335-341
( 2001).
33. H. A. Garekani, F. Sadeghi, A. Badiee, S. A. Mostafa, and A. R. ajabi-Siahboomi,
“Crystal habit modifications of ibuprofen and their physico-mechanical
characteristics,” Drug. Dev. Ind. Pharm. 27(8): 803-809 (2001).
34. 1 G. M. Khan, and Z. Jiabi, “Preparation, characterization, and evaluation of
physicochemical properties of different crystalline forms of ibuprofen,” Drug
158
Dev. Ind. Pharm. 24(5): 463-471 (1998).
35. P. D. Martino, M. Beccerica, E. Joiris, G.. F. Palmieri, A. Gayot, and S. Martelli,
“Influence of crystal habit on the compression and densification mechanism of
ibuprofen,” J. Cryst. Growth. 243(2): 345-355 (2002).
36. N. Rasenack, and B. W. Muller, “Properties of ibuprofen crystallization under
various conditions: a comparative study,” Drug Dev. Ind. Pharm. 28(9):
1077-1089 (2002).
37. V. Labhasetear, S. V. Deshmukh, and A. K. Dorle. “Studies on some crystalline
forms of ibuprofen,” Drug Dev. Ind. Pharm. 19(6): 631-641 (1993).
38. Z. Jane, and D. J. W. Grant, “Relationship between physical properties and
crystal structures of chiral drugs,” J. Pharm. Sci. 86(10): 1073-1078 (1997).
39. A. Somogyi, F. Bochner and D. Foster, “Inside the isomers: the table of chiral
switches,” Australian. Prescriber. 27(2): 47-49 (2004).
40. G. L. Perlovich, S. V. Kurkov, L. K. Hansen, and A. Baure-Brandl,
“Thermodynamics of sublimation, crystal lattice energies, and crystal structures
of racemates and enantiomers: (+)- and (+/-)-ibuprofen,” J. Pharm. Sci. 93(3):
654-666 (2004).
41. Y. Yi, D. Hatziavramidis, and A. S. Myerson, “Development of a Small-scale
automated solubility measurement apparatus,” Ind. Eng. Chem. Res. 44(15):
5427-5433 (2005).
42. R. Mohan, H. Lorenz, and A. S. Myerson, “Solubility measurement using
differential scanning calorimetry,” Ind. Eng. Chem. Res. 41(19): 4854-4862
(2002).
43. K. Park, J. M. B. Evans, and A. S. Myerson, “Determination of Solubility of
Polymorphs Using Differential Scanning Calorimetry,” Cryst. Growth Des. 3(6):
159
991-995 (2003).
44. J. S. Drury, “Miscibility of organic solvents,” Ind. Eng. Chem. 44(11): 2744
(1952).
45. N. Rasenack, and B. W. Muller, “Crystal habit and tableting behavior,” Int. J.
Pharm. 244(1-2): 45-57 (2002).
46. S. Lee, K. Nam, M. S. Kim, S. W. Jun, J. S. Park, J.S. Woo, and S. J. Hwang,
“Preparation and characterization of solid dispersions itraconazole by using
aerosol solvent extraction system improvement in drug solubility and
bioavailability,” Arch. Pharm. Res. 28(7): 866-874 (2005).
47. A.Pawar, A. Paradkar, S. Kadam, and K. Mahadik, “Agglomeration of ibuprofen
with talc by novel crystallo-co-agglomeration technique,” AAPS. PharmSciTech.
5 (4): 1-6 (2004).
48. J. M. E. Buyan, N. Shankland and D. B. Sheen, “Solvent effects on the crystal
habit of ibuprofen,” J. Pharm. Sci. 58: 1505-1509 (1969).
49. A. H. NaDa, S. M. Saleh, and B. W. Muller, “Crystal modification for improving
the physical and chemical properties of ibuprofen,” Pharm. Technol. 29(11):
90-101 (2005).
Chapter 4
1. K.J. Kim, H.S. Kim., ”Coating of Energetic Materials using Crystallization”
Chem. Eng. Technol. 28(8): 946 – 951 (2005).
2. T. Threfall, “Crystallization of polymorphs: thermodynamic insight into the role
of solvent,” Org. Process Res. Dev. 4(5): 384-390 (2000).
3. A. Chimmalgi, D. J. Hwang, and C. P. Grigoropoulos. “Nanoscale rapid melting
160
and crystallization of semiconductor thin films,” NANO LETTERS
5(10):1924-1930 (2005).
4. T. S. Kim, D.H. Kim, H.J. Im, K. Shimada, R. Kawajiri, T. Okubo, H. Murata,
and T. Mitani, “Improved lifetime of an OLED using aluminum (III) tris
(8-hydroxyquinolate),” Science and Technology of Advanced Materials. 5(3):
331–337 (2004).
5. S. Gracin, and A. C. Rasmuson, “ Solubility of phenylacetic acid,
p-hydroxyphenylacetic acid, p-aminophenylacetic acid, p-hydroxybenzoic acid,
and ibuprofen in pure solvents,” J. Chem. Eng. Data. 47(6): 1379-1383 (2002).
6. E. A. Abdel-Aal, M. M. Rashad, and H. El-Shall, “Crystallization of calcium
sulfate dihydrate at different supersaturation ratios and different free sulfate
concentrations,” Cryst. Res. Technol. 39(4): 313-321 (2004).
7. C. J. Price, “Take some solid steps to improve crystallization,” Chem. Eng. Prog.
93(9): 34-43 (1997).
8. A. S. Myerson and R. Ginde in “Handbook of industrial crystallization,” edited
by A. S. Myerson (Butterworths, Montvale, MA, ) pp 18-20 (1992).
9. J. W. Mullin, “Crystallization 3rd,” Butterworths Heinemann, London, pp
172-201 (1993).
10. L. Bromberg, J. Reshba-Step, and Terrence Scott, “Insulin particle formation in
supersaturated aqueous solutions of poly(ethylene glycol),” Biophy. J.
89(5):3424-3433 (2005).
11. A. S. Myerson and R. Ginde in “Handbook of industrial crystallization,” edited
by A. S. Myerson (Butterworths, Montvale, MA,) pp 43-51 (1992).
12. J. B. Rawlings, S. M. Miller, and W. R. Witkowski, “Model identification and
control of solution crystallization processes: a review,” Ind. Eng. Chem. Res.
161
32(7):1275-1296 (1993).
13. X.Y. Liu, “A new kinetic model for three-dimensional heterogenous nucleation,”
J. Chem. Phys. 11(4):1628-1635 (1999).
14. K. V. R. Prasad, R. I. Ristic, D. B. Sheen, and J. N. Sherwood, “Crystallization of
paracetamol from solution in the presence and absence of impurity,” Int. J.
Pharm. 215(1-2): 29-44 (2001).
15. K. Sangwal, and T. Pałczyńska, “On the supersaturation and impurity
concentration dependence of segregation coefficient in crystals grow from
solutions,” J. Cryst. Grow. 212(3-4): 522-531 (2000).
16. H. Qu, M. Louhi-Kultanen, and J. Kallas, “In-line image analysis on the effects
of additives in batch cooling crystallization,” J. Cryst. Grow. 289(2): 286-294
(2006).
17. W. Beckmann, “Seeding the desired polymorph: background, possibilities,
limitations, and case studies,” Org. Process. Res. Dev. 4(5): 372-383 (2000).
18. M. M. Rashad, M. H. H. Mahmound, I. A. Ibrahim, and E. A. Abdel-Aal, “Effect
of citric acid and 1,2-dihydroxybenzene 3,5-disulfonic acid on crystallization of
calcium sulfate dihydrate under simulated conition of phosphoric acid
production,” Cryst. Res. Technol. 40(8): 741-747 (2005).
19. S. Datta, and D. J. W. Grant, “Crystal structures of drugs: advances in
determination, prediction and engineering,” Nature 3(1):42-57 (2004).
20. Z. J. Li, M. T. Zell, E. J. Munsin, and D. J. W. Grant, “Characterization of
racemic species of chiral drugs using thermal analysis, thermodynamic
calculation, and structural studies,” J. Pharm. Sci. 88(3): 337-346 (1999).
21. T. Buhse, D. K. Kondepudi, and B. Hoskins, “Kinetics of chiral resolution in
stirred crystallization of D/L-glutamic acid,” Chirallity 11(4): 343-348 (1999).
162
22. L. Addadi, S. Weinstein, E. Gati, I. Weissbuch, and M. Lahav, “Resolution of
conglomerates with the assistance of tailor-made impurities. Generality and
mechanistic aspects of the “rule of reversal,” J. Am. Chem. Soc. 104(17):
4610-4617 (1982).
23. S. P. Duddu, F. K.Y. Fung, and D. J. W. Grant, “Effect of doping with the
opposite enantiomer on the thermodynamic properties of (-)-ephedrinium
2-naphthalenesulphonate crystals,” J. Phys. D: Appl. Phys. 26(8B): B41-B47
(1993).
24. S. P. Duddu, F. K. Y. Fung, D. J. W. Grant, “Effects of crystallization in the
presence of the opposite enantiomer on the crystal properties of
(SS)-(+)-pseudoephedrinium salicylate,” Int. J. Pharm. 127(1): 53-63 (1996).
25. Z. J. Li, and D. J. W. Grant, “Effects of excess enantiomer on the crystal
properties of a racemic compound: ephedrinium 2-naphthalenesulfonate,” Int. J.
Pharm. 137(1): 21-31 (1996).
26. M. C.Gohel,” Overview on chirality and applications of stereo-selective
dissolution testing in the formulation and development work,” Dissolution
Technologies 10(3):16-20 (2003).
27. J. F. Remenar, J. M. MacPhee, B. K. Larson, V.A. Tyagi, J. H. Ho, D. A. McIlroy,
M. B. Hickey, P. B. Shaw, and Ö. Almarsson, “Salt Selection and Simultaneous
Polymorphism Assessment via High-Throughput Crystallization: The Case of
Sertraline.,” Org. Proc. Res. Dev., 7 (6):990 -996 (2003).
28. S. L. Morissette, Ö. Almarsson, M. L. Peterson, J. F. Remenar, M. J. Read, A. V.
Lemmo, S. Ellis, M. J. Cima, C. R. Gardner,” High-throughput crystallization:
polymorphs, salts, co-crystals and solvates of pharmaceutical solids.,” Adv. Drug.
163
Deliv. Rev., 56(3):275-300 (2004).
29. A. Ridell, H. Evertsson , S. Nilsson, and L. Sundelöf, “Amphiphilic association
of ibuprofen and two nonionic cellulose derivatives in aqueous solution.,” J.
Pharm. Sci. 88(11): 1175-1181 (2000).
30. J. Israelachvili, “Intermolecular and Surface Forces, 6th” Academic Press, New
York.(1997).
31. P. Barrett, B. Smith, J. Worlitschek, V. Bracken, B. O’Sulliven, and D. O’Grady,
“A review of the use of process analytical technology for the understanding and
optimization of production batch crystallization processes,” Org. Pro. Res. Dev.
9(3): 348-355 (2005).
32. M. Birch, S. J. Fussel, P. D. Higginson, N. McDowall, and I. Marziano,
“Towards a PAT-Base strategy for crystallization development,” Org. Pro. Res.
Dev. 9(3): 360-364 (2005).
33. L. X. Yu, R. A. Lionberger, A. S. Raw, R. D’Costa, H. Wu, and A. S. Hussain,
“Applications of process analytical technology to crystallization processes,” Adv.
Drug. Del. Rev. 56(3):349-369 (2004).
34. Y Zhang and D. J. W. Grant, “Similarity in structures of racemic and
enantiomeric ibu profen sodium dihydrates.,” Acta Cryst. C61:m435-m438
(2005).
35. B. J. Armitage, J. F. Lampard, A. Smith, “Composition of S(-) Sodium
Ibuprofen.,” US Patent 6242000 (1997).
36. B. J. Armitage, J. F. Lampard, A. Smith, “Composition of S(-) Sodium
Ibuprofen.,” US Patent 5696165 (1997).
37. R. Hilfiker, S. M. D. Paul, and M. Szelagiewicz in “Polymorphism,” edited by R.
Holfiker (Wiley-Vch GmbH & Co. KGaA,) pp 287-308 (2006).
164
38. D. Winn, M. F. Doherty, “Anew technique for predicting the shape of
solution-grown organic crystals,” AIChE 44(11): 2501-2514 (1998).
39. B. R. Spong, C. P. Price, A. Jayasankar, A. J. Matzger, and N. R. Hornedo,
“General principles of pharmaceutical solid polymorphism: a supramolecular
perspective,” Adv. Drug. Del. Rev. 56(3): 241-274 (2004).
40. R. Boistelle, and J. P. Astier, “Crystallizatiom mechanisms solution,” J. Crys.
Grow. 90(1-3): 14-30 (1988).
41. D. K. Kondepudi, and K. E. Crook, “Theory of conglomerate crystallization in
the presence of chiral impurities,” Crys. Grow. Des. 5(6):2173-2179 (2005).
42. M. Kitamura, “Controlling factor of polymorphism in crystallization process,” J.
Cryst. Growth. 237–239(3): 2205–2214 (2002).
43. A. Lancia, D. Musmarra, and M. Prisciandaro, “Measure induction period for
calcium sulfate dihydrate precipition,” AIChE J. 45(2): 390-397 (1999).
44. B. Biscans, and C. Laguerie, “Determination of induction time of lysozyme
crystals by laser diffraction,” J. Phys. D: Appl. Phys. 26(8B): 118-122 (1993).
45. H. Hu, T. Hale, X. Yang, and L. J. Wilson, “A spectrophotometer-based method
for crystallization induction time period measurement,” J. Cryst. Grow. 232(1):
86-92 (2001).
46. B. K. Paul, and M. S. Joshi, “The effect of supersaturation on the induction
period of potassium dihydrogen phosphate crystals grown from aqueous
solution,” J. Phys. D: Appl. Phys. 9(8): 1253-1256 (1976).
47. N. Kubota, “Effect of impurities on the growth kinetics of crystals,” Cryst. Res.
Technol. 36(8-10): 749-769 (2001).
48. R. Siddheswaran, R. Sankar, M. Rathnakumari, R. Jayavel, P. Murugakoothan,
and P. Sureshkemar, “Nucleation, growth and characterization studies of a
165
nonlinear optical crystal-tris allylthiourea cadmium chloride (ATCC),” Laser
Phys. Lett. 3(12): 588-593 (2006).
49. R. A. Granberg, and Ǻ.C. Rasmuson, “Crystal growth rates of paracetamol in
mixtures of water + acetone + toluene,” AIChE J. 51(9): 2441-2456 (2005).
50. H. E. L. Madsen, “Crystal growth kinetics of copper phosphate from acit solution
at 37 °C,” J. Cryst. Grow. 275(1): e191-e196 (2005).
51. T. Kanagasekaran, M. Gunasekaran, P. Srinivasan, D. Jayaraman, R.
Gopalakrishnan, and P. Ramasamy, “Studies on growth, induction period,
interfacial energy and metastable zonewidth of m-nitroaniline,” Cryst. Res.
Technol. 40(12): 1128-1133 (2005).
52. W. Wu, and G.. H. Nancollas, “The relationship between surface free-energy and
kinetics in the mineralization and demineralization of dental hard tissue,” Adv.
Dent. Res. 11(4): 566-575 (1997).
53. J.W. Mullin, “Crystallization, 3rd” Butterworth-Heinemann, Oxford, Great
Britain, pp. 202-263 (1993)
54. G. Arunmozhi, E. D. M. Gomes, and S. Gansamorrthy, “Growth kinetics of
zinc(tris)thiourea sulphate (ZTS) crystals,” Cryst. Res. Technol. 39(5): 408-413
(2004).
55. P. Pantaraks, and A. E. Flood, “Effect of growth rate history on current crystal
growth: a second look at surface effects on crystal growth rates,” Cryst. Growth.
Des. 5(1): 365-371 (2005).
56. Z. J. Li, and D. J. W. Grant, “Relationship between physical properties and
crystal structures of chiral drugs,” J. Pharm. Sci. 86(10): 1073-1078 (1997).
57. G. G.Z. Zhang, S. Y.L. Paspal, R. S.Anarayanan, and D. J.W. Grand, “Racemic
species of sodium ibuprofen: characterization and polymorphic relationships,” J.
166
Pharm. Sci. 92(7): 1356-1365 (2003).
58. F. Han, J. Huang , B. Zheng, and Z. Li,” Surface properties of bolaamphiphiles in
ethanol/water mixed solutions.,” Colloids Surf., A. 242(1-3): 115-122 (2004)
59. Y. Zhang, and D. J. W. Grant, “Similarity in structures of racemic and
enantiomeric ibuprofen sodium dihydrates,” Acta Crystallogr., Sect. C. C61(Pt
9): m435-m438 (2005).
167 |
[Endnote RIS 格式]
[相關文章]
[文章引用]
[完整記錄]
[館藏目錄]
[檢視]
plurk
funp
live
udn
HD
myshare
netvibes
friend
youpush
delicious
baidu
Google bookmarks
del.icio.us
hemidemi
facebook
twitter
google
reddit